AKBA
Akebia Therapeutics, Inc.
0.9105$
+5.3%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +33.7% | -42.0% | +33.9% | -14.3% | +24.2% | +23.3% | +9.0% | -5.9% | -2.0% | -7.1% | -8.2% | – | |
| – | +3.6% | -85.5% | +205.6% | +70.7% | +43.8% | -62.6% | +30.1% | -2.2% | +25.9% | +3.3% | -17.4% | – | |
| – | +56.1% | -20.4% | +18.3% | -34.2% | +12.3% | +90.2% | +5.7% | -6.6% | -7.5% | -9.9% | -5.4% | – | |
| – | -26.0% | -1.4% | -21.4% | +11.0% | +38.9% | -17.2% | +12.9% | +32.8% | +82.2% | -44.4% | -5.1% | – | |
| – | -96.2% | +2,878.7% | +5.8% | -1.5% | -13.0% | +11.6% | +3.2% | +9.6% | -10.3% | +16.7% | -7.4% | – | |
| – | -2.5% | +24.0% | -1.7% | -18.8% | +13.0% | -10.5% | +6.3% | +16.0% | +20.9% | -15.4% | -1.3% | – | |
| – | – | -1,187.0% | – | – | – | – | +4.3% | -68.4% | -292.2% | – | – | – | |
| – | +0.6% | +76.2% | -14.0% | +210.0% | +3.2% | +13.0% | -12.0% | -30.5% | +1.7% | -2.8% | -34.5% | – | |
| – | – | -3,029.2% | – | – | – | – | -96.0% | +367.6% | -1,072.7% | – | – | – | |
| – | -100.1% | – | – | – | – | – | – | – | +64.1% | -87.5% | -44.4% | – | |
| – | – | -3,029.2% | – | – | – | – | -96.0% | +118.6% | -2,367.4% | – | – | – | |
| – | – | -143.0% | – | -437.9% | – | – | -47.9% | -15.9% | -197.8% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.